8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2008

BRUKER CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	000-30833	04-3110160
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

40 Manning Road, Billerica, MA 01821

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 435 under the Securities Act

oSoliciting material pursuant to Rule 14a-12 of the Exchange Act

oPre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

oPre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Item 2.01.Completion of Acquisition or Disposition of Assets

As described in the Current Report on Form 8-K of Bruker Corporation (the “Company”) dated February 21, 2008 (the “Initial 8-K”), on February 26, 2008, the Company completed the acquisition of all of the outstanding equity of  the companies comprising the Bruker BioSpin Group from the Bruker BioSpin Group shareholders for total consideration valued at $914.0 million, of which  approximately $388.0 million was paid in cash and approximately $526.0 million was paid in restricted unregistered shares of Company common stock, based on the trailing ten trading day average closing price of its common stock ending two days prior to the signing of the transaction agreements of $9.14 per share. Pursuant to the terms of the transaction agreements, the Company issued an agreed-upon number of 57,544,872 shares of unregistered stock, with a market value as of February 25, 2008 of approximately $624.9 million, to the Bruker BioSpin Group shareholders.

This amendment to the Initial 8-K is submitted to include the financial statements and pro forma financial information required by Item 9.01, which were omitted from the disclosure contained in the Initial 8-K pursuant to paragraph (a)(4) of Item 9.01.

Item 9.01.Financial Statements and Exhibits

(a)Financial Statements of Businesses Acquired

The audited combined financial statements of the Bruker BioSpin Group for the three years ended December 31, 2007 are attached hereto as Exhibit 99.2 and are incorporated by reference herein.

(b)Pro Forma Financial Information

The unaudited pro forma condensed combined financial statements of Bruker Corporation, giving effect to the acquisition of the Bruker BioSpin Group, are attached hereto as Exhibit 99.3 and are incorporated by reference herein.

(d)Exhibits

Number

23.1	Consent of Ernst & Young LLP
99.2	Audited Combined Financial Statements of the Bruker BioSpin Group for the three years ended December 31, 2007
99.3	Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2007 Unaudited Pro Forma Condensed Combined Statements of Operations for the three years ended December 31, 2007

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER CORPORATION (Registrant)
Date: April 11, 2008	By:	/s/  WILLIAM J. KNIGHT
		William J. Knight Chief Financial Officer and Treasurer

2

Exhibit Index

Exhibit Number	Exhibit  Name
23.1	Consent of Ernst & Young LLP
99.2	Audited Combined Financial Statements of the Bruker BioSpin Group for the three years ended December 31, 2007
99.3	Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2007 Unaudited Pro Forma Condensed Combined Statements of Operations for the three years ended December 31, 2007

3

EX-23.1

EXHIBIT 23.1

Consent of Independent Auditors

We consent to the incorporation by reference in the Registration Statement on Form S-8 (File Nos. 333-137090, 333-107294, and 333-47836) pertaining to the Bruker Biosciences Corporation Amended and Restated 2000 Stock Option Plan of our report dated April 7, 2008, with respect to the combined financial statements of Bruker BioSpin Group for each of the three years in the period ended December 31, 2007, included in this Current Report on Form 8-K/A.

	/s/ Ernst & Young LLP
Boston, Massachusetts
April 7, 2008

EX-99.2

Exhibit 99.2

Bruker BioSpin Group

Combined Financial Statements

December 31, 2007 and 2006 and for the
three years ended December 31, 2007

Contents

Report of Independent Auditors	1
Combined Financial Statements
Combined Balance Sheets	2
Combined Statements of Income	3
Combined Statements of Shareholders’ Equity	4
Combined Statements of Cash Flows	5
Notes to Combined Financial Statements	6

Report of Independent Auditors

The Shareholders

Bruker BioSpin Group

We have audited the accompanying combined balance sheets as of December 31, 2007 and 2006, of the companies listed in Note 1, and the related combined statements of income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2007. These financial statements are the responsibility of the companies’ management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the companies’ internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the companies’ internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the combined financial position at December 31, 2007 and 2006, of the companies listed in Note 1, and the combined results of their operations and their cash flows for each of the three years in the period ended December 31, 2007 in conformity with U.S. generally accepted accounting principles.

As discussed in Note 2 to the combined financial statements, effective January 1, 2007, the companies adopted Financial Accounting Standards Board Interpretation No. 48, Accounting for Uncertainty in Income Taxes. Also, as discussed in Note 17 to the combined financial statements, in 2006 the companies adopted Statement of Financial Accounting Standards (“SFAS”) No. 158, Employers Accounting for Defined Benefit Pension and Other Postretirement Plans — an amendment of FASB Statements No. 87, 88, 106 and 132(R).

                                                                                                                                                /s/ Ernst & Young LLP

Boston, Massachusetts

April 7, 2008

1

Bruker BioSpin Group

Combined Balance Sheets

(in thousands)

	December 31
	2007		2006
Assets
Current assets:
Cash and cash equivalents	$	259,492	$	259,094
Short-term investments and restricted cash	12,186		14,448
Trade accounts receivable, net of allowances for doubtful accounts of $4,171 in 2007 and $2,747 in 2006	70,279		68,089
Accounts receivable from affiliated companies	9,260		4,392
Notes receivable from affiliated companies	125		194
Inventories	278,333		276,186
Deferred income taxes	21,466		18,517
Other current assets	11,531		11,909
Total current assets	662,672		652,829
Property, plant and equipment, net	104,488		100,093
Deferred income taxes	4,252		3,174
Intangible assets	2,128		2,678
Long-term restricted cash	394		304
Long-term taxes receivable	2,643		2,606
Other assets	6,050		985
Total assets	$	782,627	$	762,669
Liabilities and shareholders’ equity
Current liabilities:
Short-term borrowings	$	179	$	—
Current portion of long-term debt	2,951		5,333
Current portion of capital lease obligation	745		665
Trade accounts payable	19,709		23,305
Accounts payable to affiliated companies	7,301		8,747
Accrued expenses and other liabilities	87,378		50,101
Customer deposits	177,610		190,276
Deferred revenue	15,797		17,346
Deferred income taxes	1,924		22,113
Income taxes payable	11,736		6,759
Total current liabilities	325,330		324,645
Deferred revenue	30,348		27,153
Long-term debt	—		4,132
Long-term capital lease obligation	2,211		2,672
Other liabilities	15,866		13,657
Deferred income taxes	24,565		4,675
Shareholders’ equity:
Common shares, $0.01 par value, authorized 20,000 shares, issued and outstanding 8,869 shares	89		89
Share capital	22,492		22,492
Additional paid-in capital	8,781		8,781
Accumulated other comprehensive income	110,626		68,832
Retained earnings	242,319		285,541
Total shareholders’ equity	384,307		385,735
Total liabilities and shareholders’ equity	$	782,627	$	762,669

 See accompanying notes.

2

Bruker BioSpin Group

Combined Statements of Income

(in thousands)

	Years Ended December 31
	2007			2006			2005
Revenue:
Magnetic resonance products	$	442,062		$	393,041		$	386,340
Service revenue	50,866			37,943			36,370
Non-core products	27,551			12,724			16,172
Other revenue	2,921			3,246			6,353
Total revenue	523,400			446,954			445,235
Costs and operating expenses:
Cost of product revenue	273,909			223,979			230,651
Cost of service revenue	31,283			23,335			22,368
Marketing and selling	50,800			47,386			45,176
Research and development	52,285			52,652			55,180
General and administrative	25,542			22,871			23,795
Acquisition charges	2,748			—			—
Special credit	—			—			(25,754		)
Total costs and operating expenses	436,567			370,223			351,416
Operating income	86,833			76,731			93,819
Interest income, net	8,566			5,543			2,391
Other (expense) income, net	(1,461		)	(4,585		)	5,612
Income before income taxes	93,938			77,689			101,822
Provision for income taxes	27,195			21,115			26,596
Net income	$	66,743		$	56,574		$	75,226

 See accompanying notes.

3

Bruker BioSpin Group

Combined Statements of Shareholders’ Equity

(in thousands)

							Accumulated
	Common				Additional		Other						Total
	Shares,		Share		Paid-in		Comprehensive			Retained			Shareholders’
	Par Value		Capital		Capital		Income			Earnings			Equity
Combined balance as of January 1, 2005	$	89	$	22,492	$	8,781	$	90,905		$	216,899		$	339,166
Dividends declared										(33,640		)	(33,640		)
Comprehensive income:
Unrealized gains on available-for-sale securities							113						113
Minimum pension liability adjustment							(414		)				(414		)
Foreign currency translation adjustment							(45,291		)				(45,291		)
Net income										75,226			75,226
Total comprehensive income													29,634
Combined balance as of December 31, 2005	89		22,492		8,781		45,313			258,485			335,160
Dividends declared										(29,518		)	(29,518		)
Effect of SFAS No. 158 adoption, net of tax provision of $1,950							(7,574		)				(7,574		)
Comprehensive income:
Unrealized gains on available-for-sale securities							202						202
Reversal of SFAS No. 87 minimum pension liability, net of tax provision of $133							(61		)				(61		)
Foreign currency translation adjustment							30,952						30,952
Net income										56,574			56,574
Total comprehensive income													87,667
Combined balance as of December 31, 2006	89		22,492		8,781		68,832			285,541			385,735
Dividends declared										(108,754		)	(108,754		)
Effect of adoption of FIN 48										(1,211		)	(1,211		)
Comprehensive income:
Unrealized gains on available-for-sale securities							495						495
Foreign currency translation adjustment							36,907						36,907
Pension plan, net of tax benefit of $1,087							4,392						4,392
Net income										66,743			66,743
Total comprehensive income													108,537
Combined balance as of December 31, 2007	$	89	$	22,492	$	8,781	$	110,626		$	242,319		$	384,307

See accompanying notes.

4

Bruker BioSpin Group

Combined Statements of Cash Flows

(in thousands)

	Years Ended December 31
	2007			2006			2005
Operating activities
Net income	$	66,743		$	56,574		$	75,226
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	15,261			14,897			14,687
Writedown of inventory to net realizable value	12,240			12,340			12,319
Deferred income taxes	885			4,052			(11,623		)
Provision for loss on contracts	(1,286		)	1,441			290
Net gain on property and equipment sales	(926		)	(78		)	(73		)
Special credit	—			—			(25,754		)
Change in net unrealized gains on available-for-sale securities	(495		)	(202		)	(113		)
Net changes in fair value of derivative assets	15			271			1,563
Changes in operating assets and liabilities:
Accounts receivable	(1,542		)	7,357			(1,145		)
Inventories	10,164			(15,233		)	(9,280		)
Other assets	719			(499		)	4,914
Accounts payable	(7,367		)	4,337			(7,884		)
Accrued expenses and other liabilities	28,824			(30,528		)	29,839
Deferred revenue	(2,346		)	3,614			1,124
Restricted cash	790			2,449			(723		)
Customer deposits	(21,699		)	(15,736		)	15,335
Net cash provided by operating activities	99,980			45,056			98,702
Investing activities
Purchases of property and equipment	(12,204		)	(13,380		)	(14,600		)
Proceeds from property and equipment sales	2,929			1,674			2,329
Collection on (disbursement on) notes from affiliated companies	(57		)	(178		)	2,414
Collection on (disbursement on) notes from third parties	(182		)	—			—
Net proceeds (purchase) of short-term investments	2,784			(3,497		)	2,056
Payments related to acquisition of Shapemetal	—			(1,643		)	—
Net cash used in investing activities	(6,730		)	(17,024		)	(7,801		)
Financing activities
Net repayments on short-term borrowings	(2,530		)	(1,337		)	(856		)
Repayments of long-term debt and capital lease obligation	(5,155		)	(9,493		)	(14,087		)
Payment of dividends	(108,754		)	(29,518		)	(33,640		)
Net cash used in financing activities	(116,439		)	(40,348		)	(48,583		)
Effects of exchange rate changes	23,587			22,628			(31,294		)
Net increase in cash and cash equivalents	398			10,312			11,024
Cash and cash equivalents at beginning of year	259,094			248,782			237,758
Cash and cash equivalents at end of year	$	259,492		$	259,094		$	248,782
Supplemental cash flow information
Cash paid for interest	$	1,300		$	1,121		$	1,671
Cash paid for taxes	21,927			43,259			15,705

 See accompanying notes.

5

Bruker BioSpin Group

Notes to Combined Financial Statements

December 31, 2007

(Dollar amounts in thousands)

1. Description of Business and Basis of Presentation

These financial statements present the combined financial position of Bruker BioSpin Inc., Bruker Physik AG, Techneon AG, Bruker BioSpin Invest AG and all of their wholly owned subsidiaries (the Bruker BioSpin Group or the Group). These companies represent companies under the control of common shareholders. All significant inter-group accounts and transactions have been eliminated in the combined financial statements. The combined financial statements have been prepared in accordance with U.S. generally accepted accounting principles.

The Bruker BioSpin Group designs, manufactures and distributes enabling life science tools based on its core technology, magnetic resonance. The Group’s core technology platforms are Nuclear Magnetic Resonance (NMR), Electro Paramagnetic Resonance (EPR), Magnetic Resonance Imaging (MRI), bench-top NMR and EPR, as well as advanced magnet technology and power supplies. The Group’s NMR division is a worldwide leader in NMR spectroscopy, with design, manufacturing and application centers in Europe, North America and Japan, as well as application and customer support facilities in most industrialized and developing countries. The Group also sells and services non-core products that are manufactured by non-combined affiliated entities. The Group’s diverse customer base includes pharmaceutical companies, biotechnology companies, academic institutions and government agencies.

Effective July 1, 2003, the Group acquired the operations of a superconducting wire manufacturer, European Advanced Superconductors (EAS) GmbH & Co KG in Hanau, Germany. The superconducting wire manufacturer is also a wire supplier to the Group’s magnet manufacturing sites. In March 2004, the Group acquired certain assets of ZFW, Gottingen, through a newly formed Bruker subsidiary, European High Temperature Superconductors (EHTS) GmbH & Co. KG. This entity provides research and development of high temperature superconductors.

6

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates.

Cash and Cash Equivalents

The Group considers all highly liquid investments with original maturities of 90 days or less at date of purchase to be cash equivalents. Certain of these investments represent deposits which are not insured by the FDIC or any other United States government agency. Cash and cash equivalents are carried at cost, which approximates fair market value.

Restricted Cash

At December 31, 2007 and 2006, the Group had $3,443 and $4,095, respectively, that was subject to restrictions in connection with advance deposits made by customers and bank performance-bid bonds. According to the terms of the various agreements, $3,049 of these funds will be released from restrictions within one year. The remaining $394 will be released at the discretion of certain government agencies and is designated as a long-term asset in the accompanying combined balance sheet at December 31, 2007.

Short-Term Investments

The Group accounts for its short-term investments in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, Accounting for Certain Investments in Debt and Equity Securities. The Group’s investments consist of money market funds that are considered to be available-for-sale and bond instruments that are considered to be trading securities at December 31, 2007 and 2006. The available-for-sale securities are reported at fair value, with unrealized gains and losses, net of tax, included as a separate component of comprehensive income. The value of these securities, as of December 31, 2007 and 2006, were $8,326 and $7,233, respectively. Unrealized gains associated with the available-for-sale securities were $495, $202, and $113 for the years ended December 31, 2007, 2006, and 2005 respectively. The bond instruments valued at $811 and $3,424

7

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

for the years ended December 31, 2007 and 2006 have maturity dates of September 2007 and February 2008. The unrealized gains from trading securities are recorded in other income.

Decreases in market values of individual securities below cost for a duration of six to nine months are deemed indicative of other than temporary impairment. Other than temporary impairments are recorded by writing down the carrying amount of the investments to market value through other income (expense). For the years ended December 31, 2007, 2006 and 2005, there were no impairment charges.

Concentration of Credit Risk

Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash equivalents, short-term investments and trade receivables. The risk with respect to cash equivalents and short-term investments is minimized by the Group’s policy of investing with high-quality financial institutions and monitoring the amount of credit exposure to any one financial institution. The risk with respect to trade receivables is minimized by the creditworthiness and diversity of the Group’s customer base. Management performs periodic credit evaluations of its customers’ financial condition, and generally requires an advanced deposit for a portion of the purchase price. The Group maintains allowances for potential credit losses, which have been within management’s expectations. For the years ended December 31, 2007, 2006, and 2005, no sales to or receivables from any single customer exceeded 10% of Bruker BioSpin Group’s revenue or accounts receivables.

Inventories

Components of inventory include raw materials, work-in-process, demonstration units and finished goods. Demonstration units include units which are located in the Group’s demonstration laboratories and at potential customer sites and are considered available for sale. Finished goods include in-transit systems that have been shipped to the Group’s customers, but not yet installed and accepted by the customer. All inventories are stated at the lower of cost or market, cost determined principally by the first-in, first-out (“FIFO”) method. The Group reduces the carrying value of its inventories for differences between the cost and estimated net realizable value taking into consideration usage in the preceding twelve months, expected demand, technological obsolescence and other information including the physical condition of demonstration and in-transit inventories.

8

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

The Group records a charge to cost of product revenue for the amount required to reduce the carrying value of inventory to net realizable value. Costs associated with the procurement and warehousing of inventories, such as inbound freight charges and purchasing and receiving costs, are included in the cost of product revenue line item within the statements of income.

Software Costs

Purchased software is capitalized and amortized over the estimated useful life, generally three years. Costs incurred developing software for use in the Group’s products are expensed as incurred and classified as research and development expense.

Property, Plant and Equipment

Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized, while expenditures for maintenance, repairs, and minor improvements are charged to expense. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the statements of income. Depreciable assets are depreciated on a straight-line basis over the estimated useful lives of the assets as follows:

Machinery and equipment	5—7 years
Furniture and equipment	3—5 years
Leasehold improvements	Lesser of 15 years or the lease term
Buildings	25—39 years

Intangible Assets

Intangible assets with a finite useful life are amortized on a straight-line basis over their estimated useful lives. Refer to Note 4 for further discussion.

9

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

Long-Lived Assets

The Group reviews long-lived assets for impairment in accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the quoted market price, if available, or the estimated undiscounted operating cash flows generated by those assets are less than the assets’ carrying value. Impairment losses are charged to the statement of income for the difference between the fair value and carrying value of the asset. No impairment losses were recorded on long-lived assets during the years ended December 31, 2007, 2006 or 2005.

Warranty Costs

The Group typically provides a one to two-year parts and labor warranty with the purchase of equipment. The anticipated cost for this warranty is accrued upon recognition of the sale and is included as a liability on the accompanying combined balance sheets.

Changes to the product warranty liability during the years ended 2007 and 2006 are as follows:

Balance at December 31, 2005	$	10,081
Warranties issued	10,984
Settlements made	(11,957		)
Foreign currency impact	886
Balance at December 31, 2006	9,994
Warranties issued	13,067
Settlements made	(11,271		)
Foreign currency impact	1,397
Balance at December 31, 2007	$	13,187
Warranties expected to be settled within one year	13,088
Warranties expected to be settled beyond one year	99
Total warranties	13,187

10

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

Customer Deposits

Under the terms and conditions of its contracts, the Group often requires an advance deposit for a portion of the purchase price of its products. These deposits are recorded as a liability until the associated revenue is recognized upon acceptance of the system.

Fair Value of Financial Instruments

The Group’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, short-term borrowings, accounts payable, long-term debt, amounts due to and from affiliated entities, notes receivable from affiliated entities and derivative instruments. The carrying value of the Group’s cash and cash equivalents, short-term investments, accounts receivable, short-term borrowings, accounts payable and amounts due to and from affiliated entities approximate fair value due to their short-term nature. The carrying values of the notes receivable from affiliated entities and long-term debt approximate fair value, estimated using interest rates available to the Group for similar items.

Foreign Currency Translation and Transactions

In accordance with SFAS No. 52, Foreign Currency Translation, all balance sheet items of foreign subsidiaries are translated into United States dollars at the current exchange rate at the balance sheet date. Results of operations of foreign subsidiaries are translated at the average exchange rate prevailing throughout the year. Resulting translation adjustments are made directly to shareholders’ equity and are included in accumulated other comprehensive income.

Gains and losses resulting from the settlement of transactions denominated in currencies other then the functional currency of the operating entity are recorded in other income (expenses).

Shipping and Handling Costs

The Group records costs incurred in connection with shipping and handling products as marketing and selling expenses. Amounts billed to customers in connection with these costs are included in product revenue. Shipping and handling costs approximated $5,343, $4,968, and $5,132 in the years ended December 31, 2007, 2006 and 2005, respectively.

11

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

Advertising Costs

Advertising costs are expensed as incurred. Advertising expenses included in marketing and selling expenses approximated $2,664, $2,477, and $1,889 for the years ended December 31, 2007, 2006 and 2005, respectively.

Revenue Recognition

The Group recognizes revenue from system sales when persuasive evidence of an arrangement exists, the price is fixed or determinable, title and risk of loss has been transferred to the customer and collectibility of the resulting receivable is reasonably assured. Title and risk of loss is generally transferred to the customer upon receipt of a signed customer acceptance for a system that has been shipped, installed, and for which the customer has been trained. As a result, the timing of customer acceptance or readiness could cause the Group’s reported revenues to differ materially from expectations. When products are sold through an independent distributor, a strategic distribution partner or an unconsolidated affiliated distributor, which assumes responsibility for installation, the Group recognizes the system as revenue when the product has been shipped and title and risk of loss has been transferred. The Group’s distributors do not have price protection rights or rights to return; however, the Group’s products are warranted to be free from defects for a period of one to two years. Revenue is deferred until cash is received when a significant portion of the fee is due over one year after delivery, installation and acceptance of the system. For arrangements with multiple elements, the Group recognizes revenue for each element based on the fair value of the element provided when all other criteria for revenue recognition have been met. The fair value for each element provided in multiple element arrangements is typically determined by referencing historical pricing policies when the element is sold separately. Changes in the Group’s ability to establish the fair value for each element in multiple element arrangements could affect the timing of revenue recognition.

Revenue from the sale of accessories and parts is recognized upon shipment and service revenue is recognized as the services are performed.

Other revenues are comprised of research grants and licensing agreements. Grant revenue is recognized as work is performed. Licensing revenue is recognized ratably over the term of the related contract.

12

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

Research and Development

Research and development costs are expensed as incurred.

Income Taxes

The Group accounts for income taxes in accordance with SFAS No. 109, Accounting for Income Taxes (“SFAS 109”). SFAS 109 requires the asset and liability approach to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. The Group records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized.

On January 1, 2007, the Group adopted the provisions of Financial Accounting Standards Board Interpretation No. 48, Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109 (“FIN No. 48”). Among other things, FIN No. 48 provides guidance to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold which an income tax position is required to meet before being recognized in the financial statements. In addition, FIN No. 48 requires expanded annual disclosures, including a rollforward of the beginning and ending aggregate unrecognized tax benefits as well as specific detail related to tax uncertainties for which it is reasonably possible the amount of unrecognized tax benefit will significantly increase or decrease within twelve months. In connection with the adoption of FIN No. 48, the Group recorded a reduction to retained earnings of $1.2 million. The Group has unrecognized tax benefits of approximately $15.0 million as of January 1, 2007, of which $6.8 million, if recognized, would result in a reduction of the Group’s effective tax rate.

Contingencies

The Group is subject to proceedings, lawsuits and other claims related to patents, products and other matters. Management assesses the likelihood of any adverse judgments or outcomes of these matters, as well as potential ranges of probable losses. A determination of the amount of reserves required, if any, for these contingencies are made after careful analysis of each individual issue. The required reserves may change in the future due to new developments in each matter or changes in approach, such as a change in settlement strategy in dealing with these matters.

13

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

Derivative Instruments

The Group manufactures and sells its products in a number of countries throughout the world and, as a result, is exposed to movements in foreign currency exchange rates. The Group periodically enters into forward currency exchange contracts and options to hedge its exposure for product sales recorded in EURO (€) currency to be redeemed in U.S. Dollars. The Group accounts for derivative financial instruments in accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, as amended, which requires that all derivative instruments be reported on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. Changes in the fair value of derivatives are recorded each period in current operations or in shareholders’ equity as other comprehensive income depending upon whether the derivative is designated as part of a hedge transaction and, if it is, the type of hedge transaction.

The Group periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. In accordance with SFAS 133, the Group accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The derivative component is marked to market in the combined balance sheet with subsequent changes in the fair value recorded in earnings.

Recent Accounting Developments

In December 2007, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 141 (revised 2007), Business Combinations (“SFAS 141R”) and SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements — an amendment of Accounting Research Bulletin No. 51 (“SFAS 160”). SFAS 141R will change how business acquisitions are accounted for and will impact financial statements both on the acquisition date and in subsequent periods. SFAS 160 will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests and classified as a component of equity. Statements 141R and 160 are effective for fiscal years beginning after December 15, 2008. Early adoption is not permitted. The Group is currently evaluating the impact, if any, these statements will have on its consolidated financial statements.

14

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

2. Summary of Significant Accounting Policies (continued)

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Liabilities, Including an amendment of FASB Statement No. 115, (“SFAS 159”). This Statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS 159 is effective as of the beginning of fiscal 2008. The Group is currently assessing the effect, if any, that the adoption of SFAS 159 will have on its results of operations and financial position.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS 157”). SFAS 157 provides a common fair value hierarchy for companies to follow in determining fair value measurements in the preparation of financial statements and expands disclosure requirements relating to how such fair value measurements were developed. SFAS 157 clarifies the principle that fair value should be based on the assumptions that the marketplace would use when pricing an asset or liability, rather than company-specific data. This Statement is effective for fiscal years beginning after November 15, 2007. However, on February 12, 2008, the FASB issued Staff Position 157-2 which delays the effective date of Statement 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. For items within its scope, this Staff Position defers the effective date of Statement 157 to fiscal years beginning after November 15, 2008. The Group is currently assessing the impact that the adoption of SFAS 157 will have on its results of operations and financial position.

Reclassifications

Certain amounts in 2006 have been reclassified to conform to 2007 presentation. Such reclassifications had no effect on previously reported net income or shareholders’ equity.

15

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

3. Acquisitions

The acquisitions below were accounted for as purchases in accordance with SFAS No. 141, Business Combinations. Under SFAS No. 141, the total consideration for the business acquisitions was first allocated to the assets acquired and liabilities assumed based on their respective fair values.

The Group acquired the superconducting wire business unit of Morgan Crucible on July 1, 2003. The transaction was to facilitate more efficient production and decrease inventory costs as the acquired business unit manufactures a primary component of the Group’s magnetic resonance systems. The terms of the acquisition called for earn-out payments based on future net revenues through 2011 to a maximum payment of €48.0 million (approximately $70.7 million at December 31, 2007). Earn-out payments of approximately $64, $5, and $5 were made for sales during the periods ended December 31, 2007, 2006, and 2005, respectively.

In March 2004, the Group acquired certain assets of ZFW, Gottingen, for an initial cash payment of approximately €350 (approximately $437 at March 1, 2004) and earn-out payments of up to €1,200 (approximately $1.78 million at December 31, 2007) for sales between 2007 and 2014. The entire purchase price of $437 represented the fair value of the patents and fixed assets acquired. The business acquired provides research and development for high temperature superconductors.

The Group entered into a Technology Transfer and Asset Purchase Agreement in December 2006 with ShapeMetal Innovation B.V., a former supplier, for a purchase price of €1,500 due in three equal installments of €500. The Group had a pre-existing relationship with ShapeMetal. The initial cash payment of €500 (approximately $660 at December 1, 2006) and milestone payments of €1,000 (approximately $1.47 million at December 31, 2007) represented the fair value of the know how and equipment acquired. The allocation of the purchase price was made based upon management estimates. The equipment, with an approximate fair value of €175, and know how, with an approximate fair value of €1,325, were acquired for the manufacturing of powder and powder in tube conductors.

16

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

4. Intangible Assets

The following is a summary of intangible assets subject to amortization as of December 31:

	2007											2006
	Useful Lives In Years	Gross Carrying Amount		Accumulated Amortization			FX effects			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			FX effects			Net Carrying Amount
Patents	3	$	219	$	(195	)	$	(24	)	—		$	198	$	(178	)	$	(9	)	$	11
Know How	4	3,737		(3,209		)	(484		)	$	44	3,378		(2,725		)	(204		)	449
Patents	5	200		(157		)	(23		)	20		181		(121		)	(6		)	54
Patents	7	954		(542		)	(71		)	341		862		(411		)	(20		)	431
Know How	10	1,933		(181		)	(29		)	1,723		1,748		(14		)	(1		)	1,733
Total amortizable intangible assets		$	7,043	$	(4,284	)	$	(631	)	$	2,128	$	6,367	$	(3,449	)	$	(240	)	$	2,678

Amortization expense related to intangible assets was $835, $1,028, and $912 for the years ended December 31, 2007, 2006 and 2005, respectively.

Estimated future amortization expense related to other intangible assets at December 31, 2007 is as follows:

Year ending:
2008	$	393
2009	330
2010	261
2011	193
2012	193
Thereafter	758
Total	$	2,128

5. Derivative Instruments and Hedging Activities

The Group had various unsettled contracts outstanding related to the purchase and delivery of certain products. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $15,221 for the delivery of products and $1,819 for the purchase of products. The comparable amounts as of December 31, 2006 were $22,504 and $122. The related net fair value recorded in accrued expenses and other liabilities was $350 and $282 as of December 31, 2007 and 2006, respectively.

17

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

6. Inventories

The components of inventory at December 31, 2007 and 2006 were as follows:

	2007		2006
Raw material	$	62,807	$	52,391
Work in process	87,325		78,470
Demonstration units	17,394		20,185
Finished goods	110,807		125,140
Total inventory	$	278,333	$	276,186

Demonstration units include systems located in the Group’s demonstration laboratories and at potential customer sites and are considered available for sale. Amortization expense for demonstration equipment was $12,240, $12,340, and $12,319 for the years ended December 31, 2007, 2006 and 2005, respectively, and is included in cost of product revenue. Finished goods include in-transit systems that have been shipped to the Group’s customers, but not yet installed and accepted by the customers. As of December 31, 2007 and 2006, inventory-in-transit was $59,549 and $81,369, respectively.

7. Property, Plant and Equipment

Property, plant and equipment, and related accumulated depreciation at December 31, 2007 and 2006, consisted of the following:

	2007			2006
Land	$	15,014		$	13,506
Furniture and equipment	136,352			120,549
Buildings	84,777			78,259
Leasehold improvements	21,019			20,026
	257,162			232,340
Less accumulated depreciation	(152,674		)	(132,247		)
Property, plant and equipment, net	$	104,488		$	100,093

Depreciation expense, which includes the amortization of leasehold improvements, for the years ended December 31, 2007, 2006 and 2005 approximated $14,426, $13,869, and $13,775, respectively.

18

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

8. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities at December 31, 2007 and 2006 consist of the following:

	2007		2006
Accrued compensation	$	24,808	$	20,725
Accrued warranty	13,088		9,879
Embedded derivative liabilities	328		282
Provision for loss on contracts	599		1,809
Withholding tax on dividends	23,416		—
Accrued expenses and other	25,139		17,406
Total accrued expenses and other current liabilities	$	87,378	$	50,101

9. Other (Expense) Income, Net

Other (expense) income at December 31, 2007, 2006 and 2005 consists of the following:

	2007			2006			2005
Exchange gains (losses) on foreign currency transactions	$	(1,829	)	$	(6,795	)	$	10,193
Appreciation (depreciation) of the fair value of derivative financial instruments	(16		)	2,094			(5,409		)
Rental income	277			90			139
Net gain on sale of property and equipment	883			22			73
Other	(776		)	4			616
Other (expense) income, net	$	(1,461	)	$	(4,585	)	$	5,612

10. Income Taxes

The domestic and foreign components of income (loss) before income taxes are as follows for the years ended December 31:

	2007		2006		2005
Domestic	$	4,449	$	3,202	$	1,200
Foreign	89,489		74,487		100,622
Total	$	93,938	$	77,689	$	101,822

19

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

10. Income Taxes (continued)

The components of the income tax provision (benefit) are as follows for the years ended December 31:

	2007			2006		2005
Current income tax expense:
Federal	$	3,126		$	607	$	1,110
State	260			253		205
Foreign	22,894			16,093		36,936
Total current income tax expense	26,280			16,953		38,251
Deferred income tax (benefit) expense:
Federal	(1,180		)	135		(733		)
State	(482		)	41		(211		)
Foreign	2,577			3,986		(10,711		)
Total deferred	915			4,162		(11,655		)
Income tax provision	$	27,195		$	21,115	$	26,596

A reconciliation of the United States federal statutory tax rate to the effective income tax rate is as follows for the years ended December 31:

	2007		2006		2005
Statutory tax rate	35.0	%	35.0	%	35.0	%
Foreign tax rate differential	(2.4	)	(5.5	)	(9.7	)
Foreign dividend withholding taxes	6.2		—		—
Change in tax rates	(6.7	)	—		—
Tax contingencies	(1.7	)	—		—
Other	(2.4	)	(3.9	)	(0.2	)
Effective tax rate before valuation allowance	28.0		25.6		25.1
Change in valuation allowance for unbenefitted losses	1.0		1.6		1.0
Effective tax rate	29.0	%	27.2	%	26.1	%

20

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

10. Income Taxes (continued)

The components of the Group’s deferred income taxes at December 31, 2007 and 2006 were as follows:

	2007			2006
Deferred tax assets:
Inventory	$	12,277		$	7,654
Deferred revenue	1,641			511
Accounts receivable	536			—
Net operating loss carryforwards	2,947			4,885
Warranty reserve	3,466			798
Compensation	618			85
Pension	—			1,016
Gross deferred tax assets	21,485			14,949
Less: valuation allowance	(3,204		)	(5,305		)
Total deferred tax assets	18,281			9,644
Deferred tax liabilities:
Accrued expenses and other	(18,323		)	(13,285		)
Excess tax over book depreciation	(265		)	(833		)
Pension	(451		)	—
Accounts receivable	—			(164		)
Short-term investments	(13		)	(459		)
Total deferred tax liabilities	(19,052		)	(14,741		)
Net deferred tax liability	$	(771	)	$	(5,097	)

The valuation allowance was determined in accordance with the provision of SFAS No. 109, which requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. For financial reporting purposes, a valuation allowance at December 31, 2007 and 2006 was recognized to offset deferred tax assets at companies in the Group where uncertainty existed with respect to future realization of deferred tax assets.

As of December 31, 2007, 2006 and 2005, net operating loss carryforwards approximating $16,649, $30,837, and $22,456, respectively, were available to reduce future foreign taxable income. Portions of the net operating loss carryforwards have no expiration dates, and others expire at various dates through the year 2017.

21

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

10. Income Taxes (continued)

On August 14, 2007, the German Business Tax Reform 2008 was signed by the Federal President and the legislative process was finalized on August 17, 2007 with the official publication of the law. This new legislation changes the German Federal Corporate Tax Rate from 25% to 15%. In addition, German Trade Tax is no longer deductible from the Corporate Income Tax. This law change, due to the benefit of revaluing our deferred tax assets and liabilities reduced the Group’s effective income tax rate by 6.8%.

No provision for United States income taxes has been made in the accompanying combined financial statements for foreign entities’ income since they are not subsidiaries of a United States corporation.

The Group has unrecognized tax benefits of approximately $13.2 million as of December 31, 2007, of which $5.3 million, if recognized, would result in a reduction of the Group’s effective tax rate. As of December 31, 2007, the Group does not expect any material changes to unrecognized tax positions within the next twelve months. A tabular reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

Gross unrecognized tax benefits at January 1, 2007	$	15,035
Gross increases — tax positions in prior period	—
Gross decreases — tax positions in prior period	(852		)
Gross increases — current period tax positions	697
Settlements	(1,653		)
Lapse of statue of limitations	—
Gross unrecognized tax benefits at December 31, 2007	$	13,227

The Group recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2007, we had approximately $1,159 of accrued interest and penalties related to uncertain tax positions included in the liability on the combined balance sheet, of which $193 was recorded during the twelve months ended December 31, 2007.

The Group considers its significant tax jurisdictions to include Switzerland, France, Germany, and the United States. The tax years 2003 to 2007 are open tax years in our major taxing jurisdictions. The Company files returns in many foreign and state jurisdictions with varying statutes of limitations.

22

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

11. Related-Party Transactions

Bruker BioSciences Corporation, SciTec GmbH and SciTec GmbH & Co. KG are related parties through common ownership with the Group. The Group and its affiliates have entered into a sharing agreement which provides for the sharing of specified intellectual property rights, services, facilities, and other related items.

The Group recognized sales to Bruker Corporation, an affiliate through common shareholders, of approximately $24,023, $21,115, and $17,074 during the years ended December 31, 2007, 2006 and 2005, respectively, and made purchases from Bruker Corporation of approximately $12,379, $11,318, and $13,029 during the years ended December 31, 2007, 2006 and 2005, respectively.

During the years ended December 31, 2007, 2006 and 2005, the Group received net payments of $3,710, $1,136, and $2,613, respectively, from Bruker Corporation for administrative and other services (including office space) provided to those entities in accordance with the terms of the shared services agreements. The amounts paid for services are based on management’s best estimates of the fair value of such services, and were recorded as a reduction of general and administrative expense in the combined financial statements.

The Group rents office space from principal shareholders under multiple leases, which have expiration dates ranging from March 31, 2010 to December 31, 2015. Total rent expense under these leases was $1,095, $1,081, and $1,078 for the years ended 2007, 2006 and 2005, respectively. The Group subleased a portion of office space from an affiliate during 2007, 2006 and 2005. The Group paid $32, $32, and $29, respectively, in rental expense, which included charges for utilities and other occupancy cost.

In November 2007, the Group sold part of an office building to ZeroC-Project GmbH in the amount of $1,137. ZeroC is a wholly owned company of one of the principal shareholders, Isolde Laukien. An independent valuation of the building was performed and the sales price was based on the estimated current market value of the building.

As of December 31, 2007 and 2006, the Group had outstanding notes receivable totaling $125 and $194, respectively, from other affiliated entities.

23

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

12. Financing Arrangements

The Group maintained several revolving lines of credit in 2007 and 2006, totaling $24,549 and $22,850, respectively, among various banks at interest rates ranging between 1.62% and 11.5%. As of December 31, 2007 and 2006, $179 and $0 were outstanding under these revolving lines of credit, respectively. Outstanding balances under these revolving lines of credit are due on demand, with interest payable monthly. The lines of credit are secured by inventory and accounts receivable, and are renewable annually.

13. Long-Term Debt

Long-term debt at December 31, 2007 and 2006 was as follows:

	2007		2006
Euro bank loan for €28.3 million. Semi-annually interest payments, due and payable through June 30, 2008 (maturity), at a rate of 4.07%.	$	2,951	$	8,147
Euro bank loan for €1 million. Quarterly interest payments, due and payable through December 1, 2009 (maturity), at a rate of EURIBOR plus 30 basis points (approximately 3.94% at December 31, 2006).	—		1,318
	2,951		9,465
Less current portion	2,951		5,333
Total long-term debt	—		$	4,132

The above notes payable are secured by certain of the Group’s assets. As of December 31, 2007 and 2006, the Group is in compliance with all debt covenants.

Interest expense for the years ended December 31, 2007, 2006 and 2005 was $515, $847, and $1,473, respectively.

14. Shareholders’ Equity

Common Shares

The Group’s shareholders’ equity includes common shares and additional paid-in capital representing shares in Bruker BioSpin Inc., a company incorporated in the United States. Each share is entitled to one vote.

24

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

14. Shareholders’ Equity (continued)

Share Capital

The Group’s shareholders’ equity includes non-par share capital of Bruker BioSpin Invest AG, a Swiss non-stock company, Bruker Physik AG, a German stock company and Techneon AG, a Swiss stock company. Share capital of the individual companies was as follows at both December 31, 2007 and 2006:

Bruker BioSpin Invest AG	$	10,011
Bruker Physik AG	7,475
Techneon AG	5,006
	$	22,492

Dividends

Dividends from German and Swiss stock companies may only be declared and paid from retained earnings (after deduction of certain reserves) shown in the companies’ statutory financial statements. Retained earnings shown in the individual companies’ statutory financial statements differ from that shown in the U.S. GAAP financial statements as a result of different bases of accounting.

In 2007 and 2006, the Board of Directors of Bruker BioSpin Invest AG declared and paid dividends of approximately $103,754 and $28,956, respectively. In 2007 and 2006, the Board of Directors of Bruker BioSpin Inc. declared and paid dividends of $5,000 and $0, respectively. In 2006, the Board of Directors of Bruker Physik AG declared and paid dividends of approximately $562.

25

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

15. Segment and Geographic Information

SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments in annual financial statements of public business enterprises. It also establishes standards for related disclosures about products and service, geographic areas and major customers. The Group evaluated its business activities that are regularly reviewed by the Group’s management, for which discrete financial information is available. As a result of this evaluation, the Group determined that it has two reportable operating segments: analytical instruments and superconducting wire. The analytical instruments business manufactures and distributes enabling life science tools based on its core technology, magnetic resonance. The superconducting wire business manufactures and distributes magnetic wire that is used in the manufacturing of these enabling life science tools.

Total revenue, cost of product revenue, operating income (loss), interest (expense) income, provision for income taxes, and depreciation and amortization for analytical instruments, superconducting wire and the combined group are as follows:

	December 31
	2007			2006			2005
Total revenue:
Analytical instruments	$	491,637		$	417,665		$	400,553
Superconducting wire	31,763			29,289			44,682
Combined	$	523,400		$	446,954		$	445,235
Cost of product and service revenue:
Analytical instruments	$	274,870		$	218,547		$	207,007
Superconducting wire	30,322			28,767			46,012
Combined	$	305,192		$	247,314		$	253,019
Operating income (loss), net:
Analytical instruments	$	94,291		$	85,348		$	106,849
Superconducting wire	(7,458		)	(8,617		)	(13,030		)
Combined	$	86,833		$	76,731		$	93,819
Interest (expense) income, net:
Analytical instruments	$	8,957		$	6,140		$	3,770
Superconducting wire	(391		)	(597		)	(1,379		)
Combined	$	8,566		$	5,543		$	2,391

26

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

15. Segment and Geographic Information (continued)

	December 31
	2007			2006			2005
Provision (benefit) for income taxes:
Analytical instruments	$	27,250		$	21,370		$	26,438
Superconducting wire	(55		)	(255		)	158
Combined	$	27,195		$	21,115		$	26,596
Depreciation and amortization:
Analytical instruments	$	12,779		$	12,085		$	12,048
Superconducting wire	2,482			2,812			2,639
Combined	$	15,261		$	14,897		$	14,687

Assets for analytical instruments, superconducting wire and the combined group are provided below:

	December 31
	2007			2006
Property, plant and equipment, net:
Analytical instruments	$	96,894		$	93,890
Superconducting wire	7,594			6,203
Combined	$	104,488		$	100,093
Capital expenditures:
Analytical instruments	$	9,668		$	11,884
Superconducting wire	2,536			1,496
Combined	$	12,204		$	13,380
Net deferred income tax liability:
Analytical instruments	$	(722	)	$	(5,097	)
Superconducting wire	(49		)	—
Combined	$	(771	)	$	(5,097	)
Total assets:
Analytical instruments	$	748,355		$	728,460
Superconducting wire	34,272			34,209
Combined	$	782,627		$	762,669

27

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

15. Segment and Geographic Information (continued)

Net income of companies in the Group outside of the United States was $64,211, $54,485, and $74,985 for the years ended December 31, 2007, 2006 and 2005, respectively.

Information concerning principal geographic areas in which the Group operates is as follows:

	2007		2006		2005
Total revenue:
Europe	$	333,878	$	281,249	$	258,585
North America	144,407		106,686		131,916
Asia	40,873		46,551		46,516
Rest of world	4,242		12,468		8,218
	$	523,400	$	446,954	$	445,235

Net revenues are attributed to the geographic area based on the location of the sales office receiving the customer order, and not necessarily the location of the customers.

	December 31
	2007		2006
Long-lived assets (year end):
Europe	$	95,370	$	91,059
North America	5,108		5,182
Asia	3,301		2,929
Rest of world	709		923
	$	104,488	$	100,093
Total assets:
Europe	$	642,522	$	601,108
North America	105,292		118,824
Asia	30,626		35,453
Rest of world	4,187		7,284
	$	782,627	$	762,669

28

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

16. Restructuring Charges

During the fiscal years ended December 31, 2006 and 2005, the Group implemented  restructuring programs in order to reduce costs and improve productivity by eliminating redundant positions, streamlining productions and initiating several cost reduction programs in all operating areas. As a result, a $468 and $2,632 charge was recorded in the years ended December 31, 2006 and 2005, respectively. The superconducting wire segment in Germany recorded $468 and $1,843 for the years ended December 31, 2006 and December 31, 2005, respectively. The analytical instruments segment in the US recorded $0 and $789 for the years ended December 31, 2006 and December 31, 2005, respectively. No restructuring charges were incurred in 2007.

The following table summarizes the restructuring charge activity and the balance of the restructuring accrual as of December 31, 2007.

	Employee Workforce Reductions			Inventory	Professional and Facility Related Fees			Total
Balance as of December 31, 2005	$	1,697		—	$	(1	)	$	1,696
New charges	468			—	—			468
Cash payments	(2,024		)	—	—			(2,024		)
Currency effects	15			—	—			15
Balance as of December 31, 2006	156			—	(1		)	155
New charges	—			—	—			—
Cash payments	(156		)	—	—			(156		)
Currency effects	—			—	1			1
Balance as of December 31, 2007	—			—	—			—

17. Employee Retirement Plans

Defined Benefit Plans

Substantially all of the Group’s employees in Switzerland, France and Japan, as well as certain employees in Germany, are covered by Group-sponsored defined benefit pension plans. Retirement benefits earned are generally based on years of service and compensation during active employment. Eligibility is generally determined in accordance with local statutory requirements. However, the level of benefits and terms of vesting may vary among plans.

29

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

17. Employee Retirement Plans (continued)

The Group adopted SFAS No. 158, Employers Accounting for Defined Benefit Pension and Other Postretirement Plans — an amendment of FASB Statements No. 87, 88, 106 and 132(R) on December 31, 2006. This Statement requires an employer to recognize the over-funded or under-funded status of defined benefit pension and other postretirement defined benefits plans, previously disclosed in the footnotes to the financial statements, as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. This Statement also requires an employer to measure the funded status of a plan as of the date of its year-end statement of financial position. In addition, this Statement requires disclosure of the effects of the unrecognized gains or losses, prior service costs and transition asset or obligation on the next fiscal year’s net periodic benefit cost.

The following table illustrates the incremental effect of applying SFAS 158 on individual line items on the Group’s balance sheet as of December 31, 2006.

	Before Application of SFAS 158		Adjustments			After Application of SFAS 158
Other assets	$	9,104	$	(8,119	)	$	985
Total assets	770,788		(8,119		)	762,669
Accrued expenses and other liabilities	49,741		360			50,101
Other long term liabilities	12,612		1,045			13,657
Deferred income taxes	24,063		(1,950		)	22,113
Total liabilities	377,479		(545		)	376,934
Accumulated other comprehensive income	76,406		(7,574		)	68,832
Total shareholders’ equity	$	393,309	$	(7,574	)	$	385,735

30

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

17. Employee Retirement Plans (continued)

The following table sets forth the funded status and amounts recognized in the combined financial statements for the various Group-sponsored defined benefit plans:

	2007			2006
Change in benefit obligation
Beginning projected benefit obligation	$	84,378		$	74,093
Service cost	2,588			2,434
Interest cost	2,494			2,168
Plan participant contributions	2,102			1,940
Benefit payments	(1,219		)	(1,847		)
Actuarial gain	(8,450		)	(470		)
Impact of foreign currency exchange rate changes	372			6,060
Ending projected benefit obligation	82,265			84,378
Change in plan assets
Fair value at beginning of year	73,277			63,724
Actual return on plan assets	1,109			2,131
Contributions	4,415			4,065
Benefits paid	(930		)	(1,779		)
Impact of foreign currency exchange rate changes	(75		)	5,136
Fair value at end of year	77,796			73,277
Net benefit obligation	$	(4,469	)	$	(11,101	)

The following amounts were recognized in the accompanying combined balance sheet for the Group’s defined benefit plans at December 31, 2007 and 2006:

	2007			2006
Non-current assets	$	4,672		$	—
Current liabilities	(276		)	(360		)
Non-current liabilities	(8,865		)	(10,741		)
Net benefit obligation	$	(4,469	)	$	(11,101	)

31

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

17. Employee Retirement Plans (continued)

The following amounts were recognized in accumulated other comprehensive income (loss) in the accompanying combined balance sheet at December 31, 2007 and 2006:

	2007			2006
Minimum pension liability, net of tax provision	$	—		$	(61	)
Net actuarial loss, net of tax provision of $863 for 2007 and $1,950 for 2006	(3,657		)	(7,574		)
	$	(3,657	)	$	(7,635	)

Weighted average assumptions used in the calculation of the pension obligation and determining the net periodic pension cost were:

	2007				2006
	Germany		Others		Germany		Others
Annual discount rate	4.00	%	2.20-5.25	%	4.00-4.25	%	2.20-4.50	%
Expected return on plan assets	—		4.25-4.43	%	—		3.78-4.25	%
Expected rate of salary increases	2.5	%	1.50-3.00	%	2.50	%	1.50-2.50	%

To determine the expected long-term rate of return on pension plan assets, the Group considers the current and expected asset allocations, as well as historical and expected returns on various categories of plan assets. For the principal pension plans, the Group applies the expected rate of return to a market-related value of assets, which stabilizes variability in assets to which that expected return is applied.

Net Periodic Pension Cost

The components of the Group’s net periodic cost are as follows:

	2007			2006			2005
Components of net periodic pension cost
Service cost	$	2,588		$	2,434		$	4,560
Interest cost	2,494			2,168			2,711
Expected return on plan assets	(2,846		)	(2,574		)	(2,427		)
Amortization of prior service cost and actuarial gains and losses	16			614			442
Net periodic pension cost	$	2,252		$	2,642		$	5,286

32

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

17. Employee Retirement Plans (continued)

Net Periodic Pension Cost (continued)

At December 31, 2007 and 2006, two of the Group’s defined benefit pension plans have an accumulated benefit obligation of $69,264 and $69,052 and plan asset fair values totaling $77,796 and $73,277, respectively. The remainder of the Group’s plans are unfunded plans with an aggregate accumulated benefit obligation of $8,354 and $8,534 as of December 31, 2007 and 2006, respectively.

As required under SFAS No. 158, the Group’s total defined benefit pension liability includes a pension asset of $4,672 related to a plan in Switzerland (Swiss Plan) and a pension liability of $491 related to a plan in France (French Plan) at December 31, 2007. The funding policy of both the Swiss and French Plans is consistent with the local government and tax requirements. The Swiss and French Plans are not required to be funded pursuant to Swiss government and tax requirements.

Asset Allocations by Asset Category

The Group’s weighted-average pension plan asset allocation at December 31, 2007 and 2006, by asset category, is as follows:

	2007		2006
Debt securities	43	%	43	%
Equity securities	31		31
Cash	12		12
Property	8		8
Mortgages	6		6
Total	100	%	100	%

Plan fiduciaries set investment policies and strategies for the trust. Long-term strategic investment objectives include preserving the funded status of the trust and balancing risk and return. The plan fiduciaries oversee the investment allocation process, which includes selecting investment managers, setting long-term strategic targets and monitoring asset allocations. Target allocation ranges are guidelines, not limitations, and occasionally plan fiduciaries will approve allocations above or below a target range.

The long-term investment strategy is to achieve a rate of return on assets of 4.5% a year. The investment strategy is limited to investing in a maximum of 35% in equity securities and a maximum of 30% in foreign currencies.

33

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

17. Employee Retirement Plans (continued)

The Group expects to contribute approximately $2,160 to its pension plans during 2008.

Estimated Future Benefit Payments

The following benefit payments, which reflect future employee service as appropriate, are expected to be paid. The benefit payments are based on the same assumptions used to measure the Group’s benefit obligation at December 31, 2007.

2008	$	1,145
2009	1,582
2010	1,750
2011	2,208
2012	2,468
2013 and beyond	18,661

Other Plans

Employees in certain other countries are covered by defined contribution plans. Generally, contributions are based on a percentage of employees’ salary. Employer contributions charged to operations were approximately $876, $750, and $864 in the years ended December 31, 2007, 2006 and 2005, respectively.

18. Accumulated Other Comprehensive Income

Comprehensive income (loss) includes net earnings and unrealized gains and losses from currency translation, marketable securities available for sale and adjustments to the funded status of pension plans, net of tax attributes. The components of the Group’s comprehensive income (loss) and the effect on earnings for the periods presented are detailed in the accompanying combined statement of shareholders’ equity.

34

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

18. Accumulated Other Comprehensive Income (continued)

The balances of each classification, net of tax attributes, within accumulated other comprehensive income (loss) as of the periods presented are as follows:

	Unrealized		SFAS No. 87			SFAS No.
	Gains on		Minimum			158					Accumulated
	Available		Pension			Pension			Foreign		Other
	For Sale		Liability			Liability			Currency		Comprehensive
	Securities		Adjustment			Adjustment			Translation		Income
Balances at January 1, 2006	$	707	$	(414	)	—			$	45,020	$	45,313
Adoption of SFAS No. 158			475			$	(8,049	)	—		(7,574		)
Other comprehensive income	202		(61		)	—			30,952		31,093
Balances at December 31, 2006	909		—			(8,049		)	75,972		68,832
Other comprehensive income	495		—			4,392			36,907		41,794
Balances at December 31, 2007	$	1,404	$	—		$	(3,657	)	$	112,879	$	110,626

19. Commitments and Contingencies

Certain companies within the Group have been parties to litigation alleging patent infringement against patents of their competitors. During 2004, the Group recorded a charge of $28,469 to cover costs associated with loss and related legal fees to the extent such amounts were deemed both probable and estimable. The related accrual for these costs was included in long-term other liabilities in the accompanying combined balance sheet at December 31, 2004. During 2005, a settlement agreement was signed for the Group’s various magnet patent litigation cases, which released the Group from any losses. As a result, the Group reversed this obligation in the amount of $25,754 during 2005. Actual legal expenses incurred were $343 during 2005.

35

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

19. Commitments and Contingencies (continued)

Operating Leases

The Group leases vehicles, office equipment and buildings under agreements expiring on various dates. Future minimum rental commitments under non-cancelable operating leases at December 31, 2007 were as follows:

2008	$	2,739
2009	2,243
2010	1,586
2011	1,297
2012	807
Thereafter	117
Total minimum lease payments	$	8,789

Rental expense under operating leases were $3,200, $2,195, and $2,821, in the years ended December 31, 2007, 2006, and 2005 respectively.

Capital Leases

The Group leases a building under an agreement that is classified as a capital lease. The cost of the building under capital lease is included in the combined balance sheets as property, plant and equipment and was $5,399 and $4,880 at December 31, 2007 and December 31, 2006, respectively. Accumulated amortization of the leased building at December 31, 2007 and December 31, 2006 was approximately $1,186 and $877, respectively. Amortization of assets under capital lease is included in depreciation expense. The future minimum lease payments required under the capital lease as of December 31, 2007 are as follows:

2008	$	746
2009	756
2010	468
2011	266
2012	279
Thereafter	441
Total minimum lease payments	2,956
Less: Current maturities of capital lease obligations	745
Long-term capital lease obligations	$	2,211

36

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

19. Commitments and Contingencies (continued)

License Agreements

The Group has entered into various technology cross-licensing agreements allowing other companies to utilize certain patents and related technologies over periods ranging from 21 to 30 years. Income from these agreements for the years ended December 31, 2007, 2006, and 2005 was $1,775, $2,101, and $2,138, respectively, and is classified as other revenues. The unearned portions of proceeds from these cross-licensing agreements are classified as short-term or long-term deferred revenue depending on when the revenue will be earned. Licensing expense for 2007, 2006, and 2005 was $680, $603, and $756, respectively.

Grants

The Group is the recipient of grants from various European government authorities. The grants were made in connection with the Group’s development of specific magnetic resonance core technology equipment. Amounts received under these grants during 2007, 2006, and 2005 totaled $1,146, $1,093, and $2,614, respectively, and are classified as other revenue. Total expenditures related to these grants in 2007, 2006, and 2005 were $550, $1,698, and $5,120, respectively. Grant-related expenditures are classified in research and development.

Guarantees

The Group maintained bank guarantees of approximately $54,526 and $61,130 for several customers as of December 31, 2007 and 2006, respectively. These arrangements guarantee the refund of advance payments received from customers in the event that the merchandise is not delivered in compliance with the terms of the contract. The sum of the guarantees is reduced by the values of the deliveries upon submission of the shipping documents.

37

Bruker BioSpin Group

Notes to Combined Financial Statements (continued)

(Dollar amounts in thousands)

20. Subsequent Events

On February 26, 2008, all of the outstanding capital stock of the Group was acquired by Bruker BioSciences Corporation in accordance with the terms of various acquisition agreements dated as of December 2, 2007. The shareholders of the Group received $914.0 million of consideration from Bruker BioSciences Corporation.

In connection with the acquisition, Bruker BioSciences Corporation entered into a five year credit agreement with a syndication of lenders that provided for a revolving credit line with a maximum commitment of $230.0 million and a term facility of $150.0 million. Under this credit facility, the Bruker BioSpin Group borrowed funds totaling $142.5 million. Borrowings under the credit agreement bear interest, at the Group’s option, at either (i) the higher of the prime rate or the federal funds rate plus 0.50%, or (ii) adjusted LIBOR, plus margins ranging from 0.40% to 1.25% and a facility fee ranging from 0.10% to 0.20%.

38

EX-99.3

EXHIBIT 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

AS OF DECEMBER 31, 2007

(in thousands)

	Bruker Corporation		Bruker BioSpin		Eliminations				Historical Combined		Pro Forma Adjustments				Pro Forma Combined
ASSETS
Current assets:
Cash and cash equivalents	$	72,876	$	259,492	$	—			$	332,368	$	(45,700	)	(3a) (3b)	$	286,668
Short-term investments and restricted cash	—		12,186		—				12,186		—				12,186
Accounts receivable, net	114,938		70,279		—				185,217		—				185,217
Due from affiliated companies	7,203		9,385		(16,588		)	(2a)	—		—				—
Inventories	171,332		278,333		(1,307		)	(2c) (2e)	448,358		—				448,358
Other current assets	29,281		32,997		—				62,278		(5,040		)	(3e)	57,238
Total current assets	395,630		662,672		(17,895		)		1,040,407		(50,740		)		989,667
Property, plant and equipment, net	103,100		104,488		—				207,588		—				207,588
Intangibles and other assets	54,483		15,467		—				69,950		2,296			(3b) (3e)	72,246
Total assets	$	553,213	$	782,627	$	(17,895	)		$	1,317,945	$	(48,444	)		$	1,269,501
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings	$	31,716	$	3,875	$	—			$	35,591	$	206,625		(3a)	$	242,216
Accounts payable	32,584		19,709		—				52,293		—				52,293
Due to affiliated companies	8,326		7,301		(15,627		)	(2a)	—		—				—
Customer deposits	55,855		177,610		—				233,465		—				233,465
Other current liabilities	124,472		116,835		(1,234		)	(2e)	240,073		—				240,073
Total current liabilities	252,953		325,330		(16,861		)		561,422		206,625				768,047
Long-term debt	6,394		—		—				6,394		144,375			(3a)	150,769
Other long-term liabilities	34,669		72,990		—				107,659		(3		)	(3e)	107,656
Minority interest	538		—		—				538		—				538
Stockholders’ equity:
Common stock	1,050		89		—				1,139		486			(3c)	1,625
Additional paid-in capital	171,508		31,273		—				202,781		106,112			(3d)	308,893
Retained earnings (accumulated deficit)	48,245		242,319		(1,034		)	(2e)	289,530		(506,039		)	(3a) (3b) (3e)	(216,509		)
Accumulated other comprehensive income	37,856		110,626		—				148,482		—				148,482
Total shareholders’ equity	258,659		384,307		(1,034		)		641,932		(399,441		)		242,491
Total liabilities and shareholders’ equity	$	553,213	$	782,627	$	(17,895	)		$	1,317,945	$	(48,444	)		$	1,269,501

See Accompanying Notes To Unaudited Pro Forma Condensed Combined Financial Statements

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2007

(in thousands, except per share data)

	Bruker Corporation			Bruker BioSpin		Eliminations				Historical Combined		Pro Forma Adjustments				Pro Forma Combined
Product revenue	$	482,153		$	469,613	$	(38,528	)	(2b)	$	913,238	$	—			$	913,238
Service revenue	64,553			50,866		—				115,419		—				115,419
Other revenue	870			2,921		—				3,791		—				3,791
Total revenue	547,576			523,400		(38,528		)		1,032,448		—				1,032,448
Cost of product revenue	252,130			273,909		(36,793		)	(2c)	489,246		—				489,246
Cost of service revenue	42,308			31,283		—				73,591		—				73,591
Total cost of revenue	294,438			305,192		(36,793		)		562,837		—				562,837
Gross profit	253,138			218,208		(1,735		)		469,611		—				469,611
Operating expenses:
Sales and marketing	105,983			50,800		—				156,783		—				156,783
General and administrative	34,058			25,542		—				59,600		—				59,600
Research and development	58,466			52,285		—				110,751		—				110,751
Acquisition related charges	4,664			2,748		—				7,412		(7,412		)	(4a)	—
Total operating expenses	203,171			131,375		—				334,546		(7,412		)		327,134
Operating income	49,967			86,833		(1,735		)		135,065		7,412				142,477
Interest and other income (expense), net	(1,355		)	7,105		—				5,750		(17,930		)	(4b)	(12,180		)
Income before income tax provision and minority interest in consolidated subsidiaries	48,612			93,938		(1,735		)		140,815		(10,518		)		130,297
Income tax provision	16,784			27,195		(701		)	(2d)	43,278		(3,002		)	(4b)	40,276
Income before minority interest in consolidated subsidiaires	31,828			66,743		(1,034		)		97,537		(7,516		)		90,021
Minority interest in consolidated subsidiaries	299			—		—				299		—				299
Net income	$	31,529		$	66,743	$	(1,034	)		$	97,238	$	(7,516	)		$	89,722
Net income per common share:
Basic	$	0.30														$	0.56
Diluted	$	0.30														$	0.55
Weighted average common shares outstanding:
Basic	103,702											57,545			(4c)	161,247
Diluted	106,769											57,545			(4c)	164,314

See Accompanying Notes To Unaudited Pro Forma Condensed Combined Financial Statements

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2006

(in thousands, except per share data)

	Bruker Corporation		Bruker BioSpin		Eliminations				Historical Combined		Pro Forma Adjustments				Pro Forma Combined
Product revenue	$	384,548	$	405,765	$	(31,781	)	(2b)	$	758,532	$	—			$	758,532
Service revenue	49,930		37,943		—				87,873		—				87,873
Other revenue	1,356		3,246		—				4,602		—				4,602
Total revenue	435,834		446,954		(31,781		)		851,007		—				851,007
Cost of product revenue	206,628		223,979		(31,425		)	(2c)	399,182		—				399,182
Cost of service revenue	29,872		23,335		—				53,207		—				53,207
Total cost of revenue	236,500		247,314		(31,425		)		452,389		—				452,389
Gross profit	199,334		199,640		(356		)		398,618		—				398,618
Operating expenses:
Sales and marketing	84,007		47,386		—				131,393		—				131,393
General and administrative	28,982		22,871		—				51,853		—				51,853
Research and development	49,959		52,652		—				102,611		—				102,611
Bruker Optics acquisition related charges	5,724		—		—				5,724		—				5,724
Total operating expenses	168,672		122,909		—				291,581		—				291,581
Operating income	30,662		76,731		(356		)		107,037		—				107,037
Interest and other income (expense), net	3,758		958		—				4,716		(17,930		)	(4b)	(13,214		)
Income before income tax provision and minority interest in consolidated subsidiaries	34,420		77,689		(356		)		111,753		(17,930		)		93,823
Income tax provision	15,931		21,115		(119		)	(2d)	36,927		(3,002		)	(4b)	33,925
Income before minority interest in consolidated subsidiaires	18,489		56,574		(237		)		74,826		(14,928		)		59,898
Minority interest in consolidated subsidiaries	8		—		—				8		—				8
Net income	$	18,481	$	56,574	$	(237	)		$	74,818	$	(14,928	)		$	59,890
Net income per common share:
Basic	$	0.18													$	0.38
Diluted	$	0.18													$	0.37
Weighted average common shares outstanding:
Basic	101,512										57,545			(4c)	159,057
Diluted	102,561										57,545			(4c)	160,106

See Accompanying Notes To Unaudited Pro Forma Condensed Combined Financial Statements

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2005

(in thousands, except per share data)

	Bruker Corporation			Bruker BioSpin			Eliminations				Historical Combined			Pro Forma Adjustments				Pro Forma Combined
Product revenue	$	329,452		$	402,512		$	(29,642	)	(2b)	$	702,322		$	—			$	702,322
Service revenue	40,471			36,370			—				76,841			—				76,841
Other revenue	2,330			6,353			—				8,683			—				8,683
Total revenue	372,253			445,235			(29,642		)		787,846			—				787,846
Cost of product revenue	178,831			230,651			(29,452		)	(2c)	380,030			—				380,030
Cost of service revenue	27,443			22,368			—				49,811			—				49,811
Total cost of revenue	206,274			253,019			(29,452		)		429,841			—				429,841
Gross profit	165,979			192,216			(190		)		358,005			—				358,005
Operating expenses:
Sales and marketing	70,458			45,176			—				115,634			—				115,634
General and administrative	25,601			23,795			—				49,396			—				49,396
Research and development	47,498			55,180			—				102,678			—				102,678
Special credit (i)	—			(25,754		)	—				(25,754		)	—				(25,754		)
Total operating expenses	143,557			98,397			—				241,954			—				241,954
Operating income	22,422			93,819			(190		)		116,051			—				116,051
Interest and other income (expense), net	(780		)	8,003			—				7,223			(17,930		)	(4b)	(10,707		)
Income before income tax provision and minority interest in consolidated subsidiaries	21,642			101,822			(190		)		123,274			(17,930		)		105,344
Income tax provision	11,855			26,596			(67		)	(2d)	38,384			(3,002		)	(4b)	35,382
Income before minority interest in consolidated subsidiaires	9,787			75,226			(123		)		84,890			(14,928		)		69,962
Minority interest in consolidated subsidiaries	40			—			—				40			—				40
Net income	$	9,747		$	75,226		$	(123	)		$	84,850		$	(14,928	)		$	69,922
Net income per common share - basic and diluted	$	0.10																$	0.44
Weighted average common shares outstanding:
Basic	100,823													57,545			(4c)	158,368
Diluted	101,130													57,545			(4c)	158,675

(i)   During 2004, the Bruker BioSpin Group recorded a pre-tax charge against operating income of $28.5 million to cover litigation expenses and probable liabilities associated with alleged patent infringement litigation by a competitor. The related accrual was included in long-term other liabilities on the condensed combined balance sheet as of December 31, 2004. In 2005, a favorable settlement agreement was signed for various magnet patent litigation cases, which released the Bruker BioSpin Group from any infringement liabilities and, as a result, a pre-tax amount of $25.8 million of this liability was reversed, which contributed positively to operating income.

See Accompanying Notes To Unaudited Pro Forma Condensed Combined Financial Statements

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

1. Description of the Transaction and Basis of Presentation

On February 26, 2008, Bruker Corporation completed the acquisition of all of the outstanding capital stock of the Bruker BioSpin Group in accordance with the terms of various agreements dated as of December 2, 2007. At the completion of these acquisitions, Bruker Corporation paid an aggregate of $914.0 million of consideration to the shareholders of the Bruker BioSpin Group, which was payable with 57,544,872 shares of unregistered common stock valued at $526.0 million, $351.0 million of cash obtained under a new credit facility and the balance with cash on hand. The value of the shares of common stock in connection with the merger was determined using a trailing average of the closing market prices of the Company’s stock for a period of ten consecutive trading days ending two days prior to the signing of the various agreements.

The six Bruker BioSpin Group shareholders, who owned approximately 52% of Bruker Corporation on an undiluted basis, also owned 100% of the stock of the Bruker BioSpin Group. As a result, this transaction was a related-party transaction. Pursuant to the acquisition agreements, completion of the transactions was subject to the approval of both a majority of Bruker Corporation shareholders and a majority of the non-affiliated Bruker Corporation shareholders who voted on the transaction. The acquisition agreements were signed among Bruker Corporation, the Bruker BioSpin Group and all of the Bruker BioSpin Group shareholders.

The following pro forma adjustments are based on available information and various estimates and assumptions. Actual adjustments will differ from the pro forma adjustments. We believe that these assumptions provide a reasonable basis for presenting the significant effects of the acquisitions and that the pro forma adjustments give appropriate effect to these assumptions and are properly applied in the Unaudited Pro Forma Condensed Combined Financial Statements.

2. Eliminations in the Combined Balance Sheet and Statements of Operations

The eliminations column in the restated combined financial statements reflects the elimination of all intercompany transactions, which include (in thousands):

(a)Adjustment to eliminate the intercompany accounts receivable and payable balances at the end of the period.

(b)Adjustment to eliminate product sales between Bruker Corporation and the Bruker BioSpin Group during the periods presented.

(c)Adjustment to eliminate product cost of sales between Bruker Corporation and the Bruker BioSpin Group during the periods presented as well as profit in inventory on the balance sheet at the end of each period.

(d)Adjustment to record the income tax provision (benefit) associated with the elimination of profit in inventory.

(e)Adjustments to eliminate profit in inventory, to reduce the income taxes payable associated with the elimination of profit in inventory and to adjust retained earnings for the period for the elimination of profit in inventory.

3. Pro Forma Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet

The Unaudited Pro Forma Condensed Combined Balance Sheet as of December 31, 2007 gives effect to the acquisition of the Bruker BioSpin Group as if it occurred on January 1, 2007. Pro forma adjustments have been made and are described below (in thousands, except share and per share data):

(a)The cash to be paid was 42.5% of the total consideration, or $388.0 million.

i.The Bruker BioSpin Group shareholders elected to receive a combination of cash and stock. The percentage of cash and stock varied for each of the individual shareholders. The trailing average of the Bruker Corporation closing price per share for the period of ten consecutive trading days ending two trading days prior to the signing of the transaction agreements was $9.14; the six shareholders received 57,544,872 shares of common stock of Bruker Corporation, with a market value of approximately $624.9 million as of February 25, 2008.

ii.The Company borrowed $351.0 million under a senior credit facility to finance a portion of the acquisition of the Bruker BioSpin Group and related expenses, which increased long-term debt by $144.4 million and short-term debt by $206.6 million at the date of closing the acquisition.

(b)Adjustments to reflect payments for estimated acquisition related costs associated with the transaction. Total acquisition related costs are estimated to be $16.1 million, of which $4.7 million and $2.7 million, respectively, were recorded on the books of Bruker Corporation and the Bruker BioSpin Group as of December 31, 2007. Acquisition related costs include investment banking, legal, accounting and antitrust regulation filing fees, and real estate transfer taxes, as well as compensation earned by the special committee of the Company’s Board of Directors and fees for establishing the senior credit facility. Of the $16.1 million of acquisition related charges referenced above, $2.9 million relates to establishing the senior credit facility, which will be capitalized and amortized over the life of the facility. The remainder of the anticipated acquisition related charges will be expensed as incurred.

(c)Adjustment to reflect the $0.01 per share par value associated with the 57,544,872 additional shares of Bruker Corporation common stock issued to the Bruker BioSpin Group shareholders in connection with the acquisition, less the elimination of the Bruker BioSpin Group common stock par value.

(d)Adjustment to reflect the additional paid in capital associated with the additional shares of Bruker Corporation common stock issued to the Bruker BioSpin Group shareholders in connection with the acquisition, offset by a deemed dividend to the affiliated shareholders.

(e)Adjustment to establish a valuation allowance for the U.S. deferred tax assets of the Bruker BioSpin Group.

4. Pro Forma Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations

The Unaudited Pro Forma Condensed Combined Statements of Operations give effect to the acquisition of the Bruker BioSpin Group as if it occurred on January 1, 2005. Pro forma adjustments have been made and are described below (in thousands, except share and per share data):

(a)We estimate that Bruker Corporation will incur merger related costs of $16.1 million related to the acquisition of the Bruker BioSpin Group. These costs include investment banking, legal, accounting and antitrust regulation filing fees, and real estate transfer taxes, as well as compensation earned by the special committee of the Company’s Board of Directors and fees for establishing the senior credit facility. We will be required to expense all of these costs in the period incurred, except for the costs related to establishing the senior credit facility, which are $2.9 million. The costs associated with establishing the senior credit facility will be amortized ratably over the life of the senior credit facility, or five years. During the year ended December 31, 2007, Bruker Corporation and the Bruker BioSpin Group incurred $7.4 million of these costs. These costs were removed as part of the pro forma adjustments as they are material, non-recurring charges directly related to the merger. The merger related costs were not tax effected because Bruker Corporation was in a net loss position for tax purposes in the U.S., the jurisdiction where the expenses were recorded.

(b)Adjustment reflects the impact of:

i.A reduction of interest income related to the cash on hand of $53.1 million used to finance a portion of the acquisition and certain acquisition-related charges. We estimate that we receive an average interest rate of 3% on cash and short-term investments, which results in a reduction to interest income of $1.6 million on an annual basis. We have assumed that this reduction in interest income would occur primarily in certain German operations and, accordingly, have recorded an associated tax benefit of $0.3 million on an annual basis.

ii.A  reduction of interest income related to the dividend of approximately $64.8 million (75 million Swiss Francs at an exchange rate of $0.86 US Dollars per Swiss Franc as of December 21, 2007). We estimate that we receive an average interest rate of 3% on cash and short-term investments,

which results in a reduction to interest income of $1.9 million on an annual basis. We have assumed that this reduction in interest income would occur primarily in certain Swiss operations and, accordingly, have recorded an associated tax benefit of $0.2 million on an annual basis.

iii.An increase in interest expense associated with the senior credit facility. We borrowed $351.0 million at an average rate of 4.1% as of February 26, 2008, to finance a portion of the Bruker BioSpin Group acquisition and to settle certain acquisition related charges, which results in an increase in interest expense of $14.4 million on an annual basis. The debt was incurred in the United States, Switzerland and Germany. The interest on the portion of the debt in the United States has not been tax effected because Bruker Corporation was in a net loss position for U.S. tax purposes as of the end of each period. We have recorded a tax benefit of $2.5 million on an annual basis related to the portion of the debt incurred in our Swiss and German subsidiaries.

(c)The change in basic and diluted average shares outstanding reflects the adjustment for the additional shares of Bruker Corporation common stock issued to the Bruker BioSpin Group shareholders upon consummation of the transaction.